- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cancer companies do battle
Zmed, a developer of image-guided radiotherapy equipment, has filed suit against Nomos in Boston federal court, alleging patent infringement by Nomos in its recently released ImageSync software on the company's tumor localization system. Zmed's SonArray,
Zmed, a developer of image-guided radiotherapy equipment, has filed suit against Nomos in Boston federal court, alleging patent infringement by Nomos in its recently released ImageSync software on the company's tumor localization system. Zmed's SonArray, an ultrasound-guided adaptive positioning system, uses stereotactic optical guidance and 3D matching software to align the tumor target to the isocenter of the radiotherapy beam. Nomos contends that its new BAT SXi device, which also uses ultrasound to align the radiation beam, does not infringe the Zmed patent, and Nomos has promised to vigorously defend itself against the litigation. Both companies claim victory in a similar court case involving the two last year.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.
